Topics

Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)

2014-08-27 03:26:18 | BioPortfolio

Summary

The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment.

- Blood pressure control

- Changing of adiponectin and plasminogen activator inhibitor-1

- Influence metabolizing and cardiac function, etc.

Description

The primary endpoints are:

- blood pressure control

- Adiponectin and plasma type1 plasminogen active inhibitor

The secondary endpoints are

- HOMA-IR

- HbA1c

- TNF

- IL-6

- Plasma B-type natriuretic peptide

- LVMI

- E/A ratio

- Tei-index

- Apo-J

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Conditions

Hypertension

Intervention

Valsartan

Location

Chuwa Tei,MD,FACC,FAHA
Kagoshima
Japan
890-8520

Status

Recruiting

Source

Kagoshima University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:26:18-0400

Clinical Trials [1440 Associated Clinical Trials listed on BioPortfolio]

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

The purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of blood pressure reduction in a patient population of mild to moderate hypertensives

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study

The purpose of this study is to compare improvement percentage of urinary albumin excretion between valsartan 80 mg- and valsartan 160 mg-based therapy in patient with morning hypertension...

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg comp...

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or ...

Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.

This trial will compare valsartan and amlodipine combination therapies to both valsartan and amlodipine, and placebo for the treatment of hypertension.

PubMed Articles [1920 Associated PubMed Articles listed on BioPortfolio]

Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.

Literature describing recovery of left ventricular (LV) function post sacubitril/valsartan treatment and the optimal management of heart failure (HF) patients receiving sacubitril/valsartan remain spa...

Selective efficacy of Sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains Sac/val and carotid fibrosis.

Sacubitril/valsartan (Sac/val) is more effective than valsartan (Val) in reducing of blood pressure (BP) and mortality in patients with heart failure. In this study we proposed that Sac/val treatment ...

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan.

Financial relationships between pharmaceutical companies and physicians can bias the conduct, findings, and reporting of clinical trials. In Japan, the valsartan scandal was a significant event: all 5...

Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.

Real-life data confirming the favourable renal outcome in patients with heart failure (HF) treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We evaluated t...

Determinants of maximal dose titration of sacubitril/valsartan in clinical practice.

Little information is available about the tolerability of uptitration to the maximal dose of sacubitril/valsartan and the predictors and clinical correlates of achieving such a dose. All consecutive h...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of amlodipine and valsartan that is used for the treatment of HYPERTENSION.

A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.

A condition in pregnant women with elevated systolic (>140 mm Hg) and diastolic (>90 mm Hg) blood pressure on at least two occasions 6 h apart. HYPERTENSION complicates 8-10% of all pregnancies, generally after 20 weeks of gestation. Gestational hypertension can be divided into several broad categories according to the complexity and associated symptoms, such as EDEMA; PROTEINURIA; SEIZURES; abnormalities in BLOOD COAGULATION and liver functions.

Hypertension due to RENAL ARTERY OBSTRUCTION or compression.

Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500

More From BioPortfolio on "Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)"

Quick Search

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...


Searches Linking to this Trial